Oncologia.mx.- Personalized medicine is a global trend that has taken root in our country and could bring great benefits to the healthcare sector. One of the greetings companies that is leading the way with studies on the subject is Roche México, in the brand of the World Dia World of DNA, realized by the virtual panel called “Recounting the history of Health, a patient in time”; and donde participant Bettina Zimmermannde Roche Farma Internacional, la Dra. Carmen Aláez of the Instituto Nacional de Medicina Genómica (INMEGEN), Dr. Carlos Sorroza López, senior medical advisor at IQVIA and the Metro. Kenji López of Cancer Warriors of Mexico, AC
The objective of the personalized medicine is that the diagnostics are temperate and with high precision, in the end each patient receives a treatment based on the specific origin of the disease, as well as quality monitoring and attention. One of the cases in which he has had great results is in the campus of oncology.
In his participation, Betina Zimmermann says that personalized medicine is the right patient, at the right time the right treatment. Personalized medicine allows nurses to considerably increase their quality of life, “and not all patients are equal and there are some treatment lines that benefit us.”
As much as, the Metro. Kenji López Cuevas, said that it is important that the goblins take into account the benefits of personalized medicine to better invert the presumption, automate the gastrointestinal tract. “Keep in mind the benefits to court and large space, less time of hospitalization and recovery of patients”, because this day is important to find dates, real lives on these treatments.
Aggregating that one of the main principles is education, “it tends to empower the patient and the decision-makers to keep the argument of the case should be implementing these treatments in the health sector in Mexico”.
Dr. Carlos Sorroza López, saying that 8% of the guest is destined to treat cancer is for diagnosis, while 70% is destined for treatments that many do not benefit patients.
Mientras que, la Dra. Carmen Aláez, habló of the importance of biomarkets and that regions that propose to develop would like to see if the applications from young people to avoid a diagnostic delay and give adequate treatment.
Aggregates that patients with Mendelian diseases, today, can benefit from this type of medicine.
The experts coincide in that it is the responsibility of all to stimulate the adoption of new ways of treating women, in this sense, the importance of empowering patients to have a more active participation in the decision-making relationship with the health of the authorities and institutions, the constant updating of medical specialists, and the contribution of the private initiative in relation to innovation and the development of new diagnostic and treatment solutions.
Finally, Rachelle Neumann, Leader of Communication for Roche México, said: The adoption of this approach represents a great opportunity to make diagnostic and treatment services more precise for the benefit of all society ”.
You may be interested in:
Only 28% of patients with LMA increase their survival rate by five years
CMOM and Pfizer collaborate to promote medical oncologists